Patents 69show all

  • 26
    A61K - Preparations for medical, dental, or toilet purposes
  • 11
    C07D - Heterocyclic compounds
  • 7
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 5
    C12N - Microorganisms or enzymes
  • 3
    C07K - Peptides
  • 3
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 3
    Y02A - Technologies for adaptation to climate change
  • 1
    A61L - Methods or apparatus for sterilising materials or objects in general
  • 1
    A61M - Devices for introducing media into, or onto, the body
  • 1
    C12Y - Enzymes

Clinical Trials 23show all

13Phase 27Phase 32Phase 1

SEC Filings show all


10
D

Contact Information

SEC Form D Funding Events

DateOfferedSoldType
2015-03-24$14,603,554$14,462,851Equity, Other
2015-02-17$9,048,000$8,740,630Equity, Other
2014-11-20$7,257,161$7,240,631Equity, Other
2014-09-05$7,117,217$6,913,123Equity, Other
2014-04-11$5,872,773$5,813,123Equity, Other
2013-05-14$5,372,769$5,313,122Equity, Other
2012-08-29$5,000,000$4,557,568Equity, Other
2010-09-20$8,300,000$8,300,000Equity, Other
2009-01-21Unknown Unknown Other (Paper Filing)

Key Executives

  • David Cory
    Executive Officer, Director
  • Ed Engleman
    Director
  • Jeffrey Glenn
    Director
  • Nina Kjellson
    Director
  • Paul Truex
    Director
  • Keith Vendola
    Executive Officer
  • Glen Sato
    Executive Officer
  • Wenjin Yang
    Executive Officer